In-silico studies for design and development of inhibitor against Covid-19

Authors

  • Akshata R. Pahelkar Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Marg, Matunga, Mumbai, 400019, Maharashtra, India
  • Pritam V. Bagwe Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Marg, Matunga, Mumbai, 400019, Maharashtra, India
  • Khushboo Maurya Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Marg, Matunga, Mumbai, 400019, Maharashtra, India
  • Nikhil R. Pahelkar Department of Biosciences and bioengineering, Indian Institute of Technology Bombay, IIT Area, Powai, Mumbai, 400076, Maharashtra, India
  • Shreerang V. Joshi Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Marg, Matunga, Mumbai, 400019, Maharashtra, India
  • Vikas N. Telvekar Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Marg, Matunga, Mumbai, 400019, Maharashtra, India

Abstract

Aim: The Covid-19 pandemic as declared by WHO, reported its first case in Wuhan, Hunei province, China. The infections have now been widespread and as of 30th March 2020, 6,93,224 infection cases and 33,106 deaths have been reported worldwide. This is an international concern related to public health. Several research studies are being carried on around the world to amid the crises. Various treatment and prevention hypothesis regarding vaccine development, repurposing of drugs along with development of new chemical entities are under investigation. Covid-19 is a virus from the coronavirus family of viruses of beta genus. It has similarity with the SARS-CoV which was reported earlier. We plan to propose a scaffold for designing peptide derived specific inhibitor against Covid-19.Method: Our strategy involves designing a peptide inhibitor that will interact with RBM of the SARS-CoV-2 and inhibit its entry inside the cell. We utilised online peptide designing platform called rosetta, Autodock Vena a computer aided drug designing software and Schrodinger’s Drug Discovery Suite Result: We propose a peptide based on the sequence of human ACE2 which interacts strongly with RBM of the SARS-CoV-2. Interested readers can utilise the sequence for further modification of the peptide sequence to convert it into a peptidomimetic.Conclusion: Receptor binding motif of SARS-CoV-2 has stronger affinity towards the derived peptide so as to terminate the infection cascade. The proposed peptide can surely be used as scaffold for designing more active agents.

Keywords:

Computer Aided Drug Design, Covid-19, Peptides, ACE 2, Spike Protein

Downloads

Download data is not yet available.

Published

01-01-2021
Statistics
50 Views | 46 Downloads

How to Cite

Akshata R. Pahelkar, Pritam V. Bagwe, Khushboo Maurya, Nikhil R. Pahelkar, Shreerang V. Joshi, and Vikas N. Telvekar. “In-Silico Studies for Design and Development of Inhibitor Against Covid-19”. Journal of Innovations in Pharmaceutical and Biological Sciences, vol. 8, no. 1, Jan. 2021, pp. 14-24, https://jipbs.com/index.php/journal/article/view/402.

Issue

Section

Research Article